Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ImmunoGen Unable To Ride Kadcyla Wave For Long; Disappoints Investors

This article was originally published in The Pink Sheet Daily

Executive Summary

The biotech is fresh off the approval of a highly anticipated breast cancer treatment, which oncology powerhouse Roche/Genentech is commercializing, but investors are already shifting their focus to the company’s lead asset, which has been made riskier by the appearance of a safety signal in Phase II.

You may also be interested in...

ImmunoGen Hopes T-DM1 Hype Shines Light On Internal Efforts

The anticipated success of the recently filed T-DM1 has offered ImmunoGen the opportunity to shine a light on its own ADC efforts.

Buoyed By T-DM1 EMILIA Data, Roche Leaps To Early Breast Cancer Trial

In Phase III EMILIA study, Herceptin-containing antibody drug conjugate demonstrates three-month progression-free survival benefit, trend toward overall survival and, importantly, better safety profile. Results pave way for new trials in earlier disease using new FDA approval pathway.

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts